{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:25:54Z","timestamp":1790886354468,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Mesonephric adenocarcinoma is a rare tumor, accounting for &lt;1% of cervical cancers. Well-differentiated mesonephric adenocarcinoma can be difficult to distinguish from diffuse mesonephric hyperplasia. Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an <jats:italic toggle=\"yes\">FGFR2<\/jats:italic> mutation not previously reported in the literature. Nonselective tyrosine kinase inhibitors or FGFR2 inhibitors may represent options for targeted therapy.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000627","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T21:29:08Z","timestamp":1563744548000},"page":"452-455","source":"Crossref","is-referenced-by-count":8,"title":["Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation"],"prefix":"10.1097","volume":"39","author":[{"given":"Stephanie L.","family":"Skala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Udager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"R1-20230824","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3892\/ijo.2015.2951","article-title":"Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing","volume":"46","author":"Takenaka","year":"2015","journal-title":"Int J Oncol"},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/1097-0142(195803\/04)11:2<334::AID-CNCR2820110217>3.0.CO;2-C","article-title":"Mesonephric lesions of the cervix; a practical means of demonstration and a suggestion of incidence","volume":"11","author":"Sneeden","year":"1958","journal-title":"Cancer"},{"key":"R3-20230824","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004347-200204000-00004","article-title":"Mitotic activity and apoptosis in endocervical glandular lesions","volume":"21","author":"Moritani","year":"2002","journal-title":"Int J Gynecol Pathol"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2559.2003.01684.x","article-title":"CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma","volume":"43","author":"McCluggage","year":"2003","journal-title":"Histopathol"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00000478-200302000-00005","article-title":"CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors","volume":"27","author":"Ordi","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2017.11.084","article-title":"Mesonephric proliferations of the female genital tract","volume":"50","author":"Howitt","year":"2018","journal-title":"Pathology"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00000478-199012000-00002","article-title":"Mesonephric remnants, hyperplasia, and neoplasia in the uterine cervix. A study of 49 cases","volume":"14","author":"Ferry","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/gyno.1993.1083","article-title":"Mesonephric remnant hyperplasia of the cervix: a clinicopathologic analysis of 14 cases","volume":"49","author":"Jones","year":"1993","journal-title":"Gynecol Oncol"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/PAS.0000000000000471","article-title":"GATA3 is a sensitive and specific marker of benign and malignant mesonephric lesions in the lower female genital tract","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0b013e31824a72c6","article-title":"Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-beta","volume":"36","author":"Kenny","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/modpathol.2015.103","article-title":"Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract","volume":"28","author":"Mirkovic","year":"2015","journal-title":"Mod Pathol"},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/his.13307","article-title":"Cervical mesonephric hyperplasia lacks KRAS\/NRAS mutations","volume":"71","author":"Mirkovic","year":"2017","journal-title":"Histopathol"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2017.02.031","article-title":"FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Jeske","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/15384047.2015.1108492","article-title":"Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations","volume":"17","author":"Kim","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-12-0999","article-title":"Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells","volume":"12","author":"Konecny","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:43:03Z","timestamp":1692841383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000627","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,18]]}}}